do you know how big this drug can be?.....it's not only going to be for double chins.......they can use it for the whole body
Peter Smith, now how do you go about estimating $1,000 a share, little rich don't you think!
The company is planning to work with the FDA to find indications where there is a "viable path to approval" for Kythera and will make the decision on where to approach first once the deal has closed.
262 of the 267 people on its "high-priority" retention list have stayed with the new Allergan.
Allergen is focused on Eluxadoline, Caripraine (two drugs on the horizon) but are still focusing on smaller drugs like IUD Liletta.
Commenting on DARPin studies, which are about to begin, the company's CEO Brent Saunders said "if it works, it's going to be huge."
Saunders also stated that the generics business is providing value to the company now.
Allergan's Chairman Paul Bisaro noted that consolidation in the sector is good for the industry.
We need to see some consolidation and execution of performance. With a few shares bought back and retired. Its going to be hard now to double the value of shares without some cash allocations somewhere.
At 130B market cap; there are things to do that aren't growth oriented any longer. The latest "acquisition" needs to be swallowed and it needs to deliver.
Cynosure Receives FDA 510(k) Clearance for SculpSure™, the World's First Hyperthermic Laser Treatment for Non-Invasive Fat Reduction
Looks only going to get you so far...its what inside that counts (lol).
You're trying to imitate and be like Phyllis Diller?
If AGN sells off because of the GREEK Exit, I would be buying more AGN. It will be yet another great buy point for AGN. You can short AGN short term at your own risk. AGN won't stay down that long. Their recent acquisition now covers the entire real estate on someone's face. All they need is Dental tooth replacement and balding hairlines and then they have it all.
Sentiment: Strong Buy